The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Trius Announces Issuance of Tedizolid Patent in China

16-Feb-2012 | Source : | Visits : 8424
SAN DIEGO - Trius Therapeutics Inc. announced today in a press release the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic of China (PRC) that protects the composition of matter of the Company's Phase 3 investigational drug, tedizolid phosphate, through 2024. In addition to the issuance in China, patents for tedizolid phosphate have also issued in other jurisdictions including Australia, Canada, Europe, India, Japan, Mexico, Russia and the United States. 

"The issuance of the tedizolid patent in China exemplifies Trius' commitment to engaging in key emerging markets both directly and through our strategic partners," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius. "China is the world's largest emerging pharmaceutical market, and Trius continues to focus on maximizing the commercial potential of tedizolid in both the high growth emerging markets as well in the key traditional markets." 

Trius licensed the rights to tedizolid phosphate for Asia-Pacific and emerging markets to Bayer Pharmaceuticals and recently announced receiving a $5 million milestone payment from Bayer after the successful completion of the "112" Phase 3 clinical study of tedizolid phosphate in acute bacterial skin and skin structure infections (ABSSSI). Trius retains the rights to tedizolid in the US, Canada and the EU countries. 

Trius Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.


Related Articles